CTC report

Bronwen Shaw – chairbshaw@doctors.org.uk

Andy Peniket – secretaryAndy.Peniket@ouh.nhs.uk

CTC operations

• Meet 3/year: next meeting 14th November BSH House

• New processes working well– Each meeting preceded in am by ‘PI’ meeting for specific

studies (PI plus office staff). Many PIs have taken advantage of this

– Regular teleconferences – review progress of each study, invite specific PIs

• Letter of understanding for PIs

CTC activity: manuscripts•Published

–GvL in ALL (Medd et al)–outcomes in severe autoimmune disease (Snowden et al)–results of RIC allos for mantle cell lymphoma (Cook et al)–a comparison of ATG vs Alemtuzumab based conditioning in aplastic anaemia (Marsh et al)

•Preparation/submitted–second allogeneic transplants (Lown et al)–impact of KIR on AML transplant outcomes (Schellekens et al)–pulmonary function post allograft (brown et al) –BEAM-campath for lymphoproliferative disorders (Fox et al) –refractory myeloma (Cook et al)–impact of pre-transplant campath in CLL (Protheroe et al)–Allo SCT in elderly patients (Nikolousis/Craddock et al)–Cord blood retrospective analysis (Snowden/Rocha et al) – joint study with Eurocord

•Analysis: Impact of HLA matching on survival (Shaw et al)

CTC activity: supporting ongoing prospective studies

• The FIGARO study for high risk AML has just opened (Craddock)

• Myeloma X (Cook)• National cord blood studies (Hough) and immune reconstitution• Hodgkin’s study (Peggs)• MCL study (Rule) • Haplo-identical transplant protocols (Raj/Mackinnon/Pagliuca)

• Prospective data collection studies • co-morbidities (Gilleece) • intracranial haemorrhage (Stanworth)

CTC activity: new proposals•In development– mesenchymal stromal cells (Dazzi)– invariant NKT cells (Karadimitris)– Myelofibrosis trial (Mead/Gilleece)

•New projects:– paediatric refractory AML (O’Hare)– incidence and risks or TTP (Hill)– second line treatments for acute GvHD (Das Gupta)

•Surveys:– Late effects (Snowden)– EBV monitoring (Hamblin)